Biocorp and RxPack have announced a new distribution agreement giving RxPack the exclusive rights to commercialize Biocorp’s Inspair inhaler sensor in Eastern Europe, Southeast Asia, South America, and the Middle East. Lindal had obtained the rights to market Inspair in those territories in 2018, and RxPack is a joint venture of Lindal and Coster which was formed in 2021.
Biocorp launched the Inspair sensor, which fits onto standard MDIs, in 2016. In December 2021, Biocorp and H&T Presspart announced that H&T Presspart would market Inspair; no territories were specified in that announcement.
RxPack CEO Massimo Carrara commented, “We are excited to welcome Biocorp among our preferred partners. We believe digital smart delivery enables better patients’ compliance, that is fundamental for good therapy outcomes. Biocorp is a leading company in the field of smartification of pharma delivery systems. We are certain that e-connected devices will lead the way in the respiratory field in the years to come.”
Biocorp CEO Eric Dessertenne said, “We are delighted to be working with RxPack to distribute Inspair to a wide range of countries. This is another major marketing agreement for Biocorp, this time for our connected inhaler solution. Chronic respiratory diseases such as asthma and COPD are on the rise worldwide and require more than ever good compliance and monitoring of patients at the risk of seeing their condition worsen dramatically.”
Read the Biocorp and RxPack press release.
